. Mean platelet volume (MPV) is a marker of activated platelets and is related to different inflammatory conditions (Gasparyan et al.,2011) . Changed MPV levels were observed in gastric cancer, ovarian cancer, lung cancer, colon cancer, and breast cancer (Gu et al., 2015; Kemal et al., 2014; Kilincalp et al., 2014; Kumagai et al., 2015; . Platelet distribution width (PDW), another platelet index, indicates variation in platelet size. However, the clinical implication of PDW in cancer is unclear.
The relationship between platelet indices and GBC has not yet been studied. The aim of the current study was to investigate the association of MPV and PDW with GBC.
Materials and Methods
A total 104 GBC patients (mean age 60.3 ± 10.5 years, range 36-84 years) and 109 normal control subjects (mean age 60.2 ± 3.6 years, range 54-71 years) participated in the present study. All patients undergone surgical resection in Harbin Medical University Cancer Hospital between January 2015 and December 2015. The diagnosis of GBC was confirmed by histology. None of the patients received chemotherapy or radiotherapy prior to surgery. The exclusion criteria included hematological disorders, coronary artery disease, hypertension, diabetes mellitus, and medical treatment with anticoagulant, statins, and acetylic salicylic acid. The control subjects were recruited from Harbin Medical University Cancer Hospital, Harbin Medical University. They were matched for age, gender, body mass index (BMI), and smoking status.
This study was approved by the Institutional Review Board of Harbin Medical University Cancer Hospital and all subjects provided written informed consent.
Clinical examination and biochemical measurements
Clinical data including smoking status, medical history and medication use were recorded for each subject. Preoperative blood samples after a 10-hour overnight fasting were collected from the individuals. White blood cell (WBC), haemoglobin, and platelet indices were analyzed by an autoanalyzer (Sysmex XE-2100, Kobe, Japan). The whole blood samples were collected in EDTA-containing tubes, and were processed within 30 minutes after blood collection. The inter-and intra-assays coefficients of variation (CVs) of all these assays were below 5%. All the measurements were performed blinded to the clinical data.
Statistics
Data for continuous variables were presented using the number of subjects, the means ± SD or median values. Significance differences of clinicopathological parameters between groups were determined with the Student's t test, Mann-Whitney U test, or Chi-square test based on the type of the data. The odds ratios (ORs) and 95% confidence intervals (95% CIs) for GBC were calculated after adjusting for confounding variables across MPV and PDW quartiles using multivariate logistic regression analysis. P < 0.05 was considered to indicate a statistically significant difference. All data analyses were performed using SPSS Statistics version 22.0 (SPSS Inc., Chicago, IL, USA).
Results
The study consisted of 104 GBC patients, and 109 control subjects between January 2015 and December 2015. Of the 213 participants enrolled, 106 (49.8%) were men and 107 (50.2%) were women. The mean ages were 61.0 ± 6.3 and 59.6 ± 9.0 years, respectively.
The characteristics of GBC patients, and control subjects are presented in Table 1 . GBC patients had lower MPV and haemoglobin levels and higher PDW compared to control subjects (p<0.001). However, there was no difference in age, gender, smoking status, alcohol intake, body mass index, fasting plasma glucose, platelet count, and white blood cell in two groups.
Correlations between clinicopathological characteristics and platelet indices in GBC are summarized in Table 2 . Platelet count correlated with pathologic T stage, lymph node metastasis and TNM stage. PDW correlated with lymph node metastasis. However, there were no correlations between platelet count and MPV and tumor size, tumor differentiation, and perineural invasion.
To understand the relationship between MPV and PDW levels and the prevalence of GBC, the subjects were classified into quartiles by their MPV and PDW levels. The prevalence of GBC in participants with different increased (ptrend < 0.001).
The risks for GBC according to MPV and PDW quartiles are listed in Table 3 . In multiple logistic regression model, after adjusting for age, sex, smoking status, body mass index, fasting plasma glucose, white blood cell, and haemoglobin, the corresponding ORs (95% CI) for GBC across MPV quartiles were 5.117 (1.939-13.506), 2.444 (0.917-6.516), 3.718 (1.381-10.007), and 1.000, respectively. Similarly, the ORs (95% CI) for GBC across PDW quartiles were 1.000, 2.063 (0.825-5.162), 3.070 (1.108-8.507), and 12.108 (4.243-34.553), respectively.
Discussion
In this study, we provided evidence that platelets is activated in GBC using a simple, relatively inexpensive, almost universally obtained test. The GBC patients had lower MPV and higher PDW compared to the controls. Furthermore, MPV and PDW were independently associated with GBC.
Platelets act as a key modulator in tumor development, angiogenesis, and metastasis. Several reports found that thrombocytosis is associated with poor prognosis in various types of cancers, including lung cancer, ovary cancer, endometrium cancer, rectum cancer, renal cancer, gastric cancer, pancreas cancer, and breast cancer. Some quartile levels of MPV and PDW were analyzed. For MPV, the prevalence of GBC in Q1, Q2, Q3, and Q4 was 67.2% (39/58), 44.0% (22/50), 49.1% (27/55), and 32.0% (16/50), respectively (Figure 1 ). For PDW, the prevalence of GBC in Q1, Q2, Q3, and Q4 was 25.9% (14/54), 41.3% (26/63), 57.8% (26/45), and 74.5% (38/51), respectively (Figure 2) . The results indicated that the prevalence of GBC decreased as MPV quartiles increased (ptrend < 0.001) and increased as PDW quartiles Table 3 . ORs and 95% CIs for GBC According to MPV and PDW Quartiles clinical studies have found the altered indicators of platelet activation, such as soluble P-selectin, CD40 ligand, and β-thromboglobulin (β-TG) in patients with cancer (Al-Mondhiry, 1983; Ay et al., 2008; Huang et al., 2012) . However, these parameters reflecting platelets activation were not routinely used in clinical practice and can not be easily evaluated prior to treatment. MPV levels are routinely recorded in the clinical setting and can be easily estimated prior to treatment. Thus, MPV might be useful in early detection and in creating an individual patient therapy plan. However, the change of MPV and PDW in different types of cancers is inconsistent. Higher MPV was observed in gastric cancer and ovarian cancer (Kemal et al., 2014; Shen et al., 2016) . Moreover, increased PDW was found in gastric cancer and lung cancer (Gunaldi et al.,2016; Oncel et al., 2015) . In contrast, reduced PDW was noted in thyroid cancer and breast cancer (Okuturlar et al., 2015; Yaylaci et al., 2016) . The conflicting data may be due to small sample sizes, failure to rule out confounding factors, different tumor types, and selected populations. Therefore, further research on MPV and PDW levels in different cancers is warranted.
The molecular mechanisms underlying the association of MPV and PDW with GBC are poorly understood. Bone marrow cells (including megakaryocytes) dys-regulation may contribute to altered MPV and PDW. Platelet volume is determined both during megakaryopoiesis and during thrombopoiesis. Megakaryocytic maturation, platelet production and platelet size could be modulated by cytokines, such as interleukin-6 (IL-6), granulocytes colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) (Kaushansky,1998) . Increased interleukin-6 (IL-6) has been verified in almost all types of tumors acting as a major cytokine in the tumor microenvironment (Lippitz and Harris, 2016) . Several lines of evidence revealed that IL-6 overexpression promotes tumorigenesis by regulating apoptosis, survival, proliferation, angiogenesis, metastasis and metabolism (Kumari et al., 2016) . Moreover, the cytokines G-CSF and M-CSF secreted by tumor cells could stimulate megakaryopoiesis and subsequent thrombopoiesis in cancer (Kowanetz et al., 2010) . MPV was an early index of activated platelets. Decreased MPV could be a result of an enhanced consumption of large platelets in inflammatory states (Gasparyan et al., 2011) . In addition, MPV has been reported to be positively associated with the levels of thrombopoietin and interleukin-6 which regulate megakaryocyte ploidy (Brown et al., 1997; Martin et al., 1983) . More experiments need to be carried out to explore the molecular mechanism for the change of MPV and PDW in GBC.
Considerable evidence supports the association between activated platelets and cancer in clinical studies. In this study, we showed the association between activated platelets and GBC using a convenient and inexpensive marker. This marker may be a complement to the present biomarkers and a benefit to the early detection of GBC.
The present study has several limitations. First, we analyzed the subjects cross-sectionally and this type of study fails to indicate a causal relationship between MPV and PDW and GBC. Second, this is a study carried out in a single hospital. Therefore, prospective studies are needed to illuminate the relationship between MPV and PDW and GBC.
In conclusion, the study found that MPV was independently associated with the GBC. Further studies on the involvement of MPV in GBC are needed.
